BIAF Key Statistics, Chart & Performance
The current stock price of BIAF is 0.8512 USD. In the past month the price decreased by -34.02%. In the past year, price decreased by -96.36%.
BIAF Technical Analysis
BIAF Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIAF. BIAF may be in some trouble as it scores bad on both profitability and health.
BIAF Financial Highlights
Over the last trailing twelve months BIAF reported a non-GAAP Earnings per Share(EPS) of -20.94. The EPS increased by 13.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.65% | ||
| ROE | -165.57% | ||
| Debt/Equity | 0.01 |
BIAF Forecast & Estimates
For the next year, analysts expect an EPS growth of 41.46% and a revenue growth -36.4% for BIAF
BIAF Ownership
BIAF Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIAF
Company Profile
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Company Info
BIOAFFINITY TECHNOLOGIES INC
3300 Nacogdoches Road, Suite 216
San Antonio TEXAS US
Employees: 57
Phone: 12106985334
BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ
Can you describe the business of BIOAFFINITY TECHNOLOGIES INC?
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
What is the current price of BIAF stock?
The current stock price of BIAF is 0.8512 USD. The price increased by 13.49% in the last trading session.
What is the dividend status of BIOAFFINITY TECHNOLOGIES INC?
BIAF does not pay a dividend.
What is the ChartMill rating of BIOAFFINITY TECHNOLOGIES INC stock?
BIAF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in BIOAFFINITY TECHNOLOGIES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIAF.
When does BIOAFFINITY TECHNOLOGIES INC (BIAF) report earnings?
BIOAFFINITY TECHNOLOGIES INC (BIAF) will report earnings on 2026-03-30.